Skip to main content

Table 1 Tau imaging agents: from basic to clinical applications

From: In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals

Basic research The combination of Tau imaging agents and transgenic models can allow for:
  a) Non-invasive longitudinal tracking of tau pathology
b) Longitudinal assessment of behavior as a function of tau pathology
c) Determination of pharmacokinetic properties
d) Development of novel radiopharmaceuticals
e) Development of theoretical models regarding progression of tau pathology
Clinical applications The use of Tau imaging agents in the clinical approach can allow for:
  a) Early diagnosis
b) Differential diagnosis
c) Follow-up of cognitive decline as function of tau pathology progression
d) Monitoring of treatment effectiveness of novel anti-tau and associated therapies
e) Development of theoretical models regarding tau pathology progression
f) Estimation of sample size and endpoints in the context of clinical trials